Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2001

View Archived Issues

Licensing opportunity from NIH: magnetic stimulator for drug addiction and depression

Licensing opportunity from NIH: conjugate cholera vaccines

Ophidian and Hemoxymed to merge

Zarix licenses anticancer/antifungal agent from Chiron

PPL Therapeutics provides update on rAAT and BSSL

Expansion of clinical pipeline planned at Meiji Seika

Sustained beneficial effects seen for ALT-711 on arterial and ventricular parameters in aged monkeys

Efficient synthesis of new HNE inhibitor GW-475151

InKine obtains development and marketing rights to IBStat

Aradigm and Genentech discontinue AERx rhDNase development program

Candelalides as Kv1.3 channel blockers and potential immunosuppressants

FDA approves Pfizer's ziprasidone for schizophrenia

Enzyme replacement therapy has potential to alleviate main symptoms of MPS-I

MAA for UT-15 filed in France; new name accepted

E.U. approves Remicade for broader RA indication

Phase I leukemia data on Troxatyl published

Antigenics' genital herpes agent receives FDA clearance for clinical trials

Orion claims new use for levosimendan

Formulation of glibenclamide with excellent percutaneous absorption

Monoclonal antibodies against alphavbeta3 integrin designed at former Searle

IND candidate for stroke selected by Incara from catalytic antioxidant series

FDA approves tablet formulation of CollaGenex's Periostat

Pyrazole-based inhibitors of p38 MAP kinase identified at Teikoku Hormone

DuPont presents new serotonergic compounds for CNS and GI disorders

Sigma receptor ligands reported to exert immunosuppressive and other effects

Potent and selective dopamine D4 receptor ligands and their use described by Neurogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...